[go: up one dir, main page]

BRPI1004922A2 - composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama - Google Patents

composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama

Info

Publication number
BRPI1004922A2
BRPI1004922A2 BRPI1004922A BRPI1004922A BRPI1004922A2 BR PI1004922 A2 BRPI1004922 A2 BR PI1004922A2 BR PI1004922 A BRPI1004922 A BR PI1004922A BR PI1004922 A BRPI1004922 A BR PI1004922A BR PI1004922 A2 BRPI1004922 A2 BR PI1004922A2
Authority
BR
Brazil
Prior art keywords
hodgkin
lymphoma
disease
treatment
pharmaceutical composition
Prior art date
Application number
BRPI1004922A
Other languages
English (en)
Inventor
R Haltiwanger Curtis
D Courvoisier Laurent
Eddleston Mark
E Mckean Robert
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1004922(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of BRPI1004922A2 publication Critical patent/BRPI1004922A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1004922A 2009-01-15 2010-01-14 composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama BRPI1004922A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Publications (1)

Publication Number Publication Date
BRPI1004922A2 true BRPI1004922A2 (pt) 2019-09-24

Family

ID=42008533

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1004922A BRPI1004922A2 (pt) 2009-01-15 2010-01-14 composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama

Country Status (16)

Country Link
US (1) US8076366B2 (pt)
EP (1) EP2387400A1 (pt)
JP (1) JP2012515210A (pt)
KR (1) KR20110110293A (pt)
CN (2) CN102281877B (pt)
AU (2) AU2010204765A1 (pt)
BR (1) BRPI1004922A2 (pt)
CA (1) CA2749101A1 (pt)
EA (1) EA020767B1 (pt)
IL (1) IL213725A0 (pt)
MX (1) MX2011007557A (pt)
NZ (1) NZ594010A (pt)
SG (1) SG172810A1 (pt)
UA (1) UA109109C2 (pt)
WO (1) WO2010083276A1 (pt)
ZA (1) ZA201105099B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079193A2 (en) * 2009-12-23 2011-06-30 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
PT2528602T (pt) 2010-01-28 2017-01-12 Eagle Pharmaceuticals Inc Formulações de bendamustina
US9273010B2 (en) * 2011-06-20 2016-03-01 Hetero Research Foundation Process for bendamustine hydrochloride
SI3533447T1 (sl) 2012-03-20 2023-06-30 Eagle Pharmaceuticals, Inc. Tekoči sestavki bendamustina za uporabo v postopku zdravljenja na bendamustin odzivnih stanj pri bolnikih,pri katerih so potrebni zmanjšani volumni za dajanje
FI2827862T3 (fi) 2012-03-20 2024-02-13 Eagle Pharmaceuticals Inc Bendamustiinin formulaatioita
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
ES2670995T3 (es) * 2013-03-12 2018-06-04 Cephalon, Inc. Formulaciones de nanopartículas y macropartículas
CN105142497B (zh) 2013-04-26 2018-01-12 维塔尔艺术与科学有限责任公司 轮廓线融合视野检查视力测试
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (pt)
DE159877C (pt)
DE293808C (pt)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1995011683A1 (en) 1993-10-27 1995-05-04 The Upjohn Company Stabilized prostaglandin e¿1?
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
EP1104297B8 (en) 1998-07-09 2006-05-03 Cephalon, Inc. Compositions for the treatment of chronic lymphocytic leukemia
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
HUP0400683A2 (hu) 2000-12-11 2004-06-28 Takeda Chemical Industries, Ltd. HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény
HUP0401811A2 (hu) 2000-12-11 2004-12-28 Takeda Chemical Industries, Ltd. Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
US8679520B2 (en) 2001-10-15 2014-03-25 Hemoteq Ag Coating of stents for preventing restenosis
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
JP4443935B2 (ja) 2002-03-22 2010-03-31 ルートヴィヒ マクシミリアン ウニヴェルジテート 高用量細胞傷害性化学療法後の造血回復、好中球減少性発熱、および抗菌処置の予測のための細胞能力試験
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
BR0310008A (pt) 2002-05-09 2005-02-15 Hemoteq Gmbh Preparação, método e uso de revestimentos hemocompatìveis para a prevenção de restenose
WO2004012769A1 (en) 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004074325A2 (en) 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
SG144165A1 (en) 2003-07-25 2008-07-29 Wyeth Corp Cci-779 lyophilized formulations
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN102177140B (zh) * 2008-10-08 2016-01-27 赛福伦公司 用于制备苯达莫司汀的方法

Also Published As

Publication number Publication date
SG172810A1 (en) 2011-08-29
MX2011007557A (es) 2011-08-12
AU2016204902A1 (en) 2016-08-04
IL213725A0 (en) 2011-07-31
KR20110110293A (ko) 2011-10-06
CN102281877B (zh) 2014-07-23
NZ594010A (en) 2013-08-30
AU2010204765A1 (en) 2011-07-28
CN103554030A (zh) 2014-02-05
CN102281877A (zh) 2011-12-14
US20100210701A1 (en) 2010-08-19
EP2387400A1 (en) 2011-11-23
CA2749101A1 (en) 2010-07-22
ZA201105099B (en) 2012-03-28
WO2010083276A1 (en) 2010-07-22
UA109109C2 (uk) 2015-07-27
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
US8076366B2 (en) 2011-12-13
JP2012515210A (ja) 2012-07-05

Similar Documents

Publication Publication Date Title
BRPI1004922A2 (pt) composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama
CL2009000742A1 (es) Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama.
EP2496545A4 (en) SULFOMETHYL SUCCINATE, PROCESS FOR THE PRODUCTION THEREOF AND COMPOSITIONS THEREWITH
EP2186837A4 (en) ABA-TRIBLOCK COPOLYMER AND MANUFACTURING METHOD THEREFOR
EP2474539A4 (en) DIEPOXY COMPOUND, PREPARATION METHOD AND COMPOSITION WITH THE DIEXOXY COMPOUND
BRPI0810206A2 (pt) Método de tratar câncer
IT1399202B1 (it) Metodo per la produzione di manufatti elastomerici funzionalizzati e manufatti cosi' ottenuti
EP2150409A4 (en) POLYOLEFIN-TARPAULIN COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
EP2903471A4 (en) ADHESIVE, WASHABLE, ANTIMICROBIAL INSERT FOR SHOES AND METHOD FOR THE MANUFACTURE THEREOF
EP2763192A4 (en) NITRIDE SEMICONDUCTOR ELEMENT AND MANUFACTURING METHOD THEREFOR
BRPI0918014A2 (pt) produção de propileno integrada
FR2987838B1 (fr) Polyolefine telechelique, et son procede d'obtention
BRPI0914449A2 (pt) "método de fabricação de artigo absorvente"
EP2578607A4 (en) TERMINAL UNSATURATED POLYOLEFIN AND MANUFACTURING METHOD THEREFOR
DE502008000766D1 (de) Blasmaschine mit Garniturteilhalter, sowie Garniturteilhalter
EP2703466A4 (en) COMPOUND OF A WATER REPELLENT AND AN OIL-REACTIVE AGENT, PRODUCTION METHOD AND ARTICLE THEREOF
EP2163619A4 (en) ROSE WITH FLAVON AND MALVIDINE AND METHOD OF MANUFACTURE THEREOF
FR2956980B1 (fr) Harnais d'encordement a repartiteur d'efforts, et son procede de fabrication
BRPI0819744A2 (pt) Processo do floco de batata doce
EP2650049A4 (en) HYDROGEN TREATMENT CATALYST AND METHOD FOR THE PRODUCTION THEREOF
EP2159282A4 (en) ROSE-FLAVON AND DELPHINIDINE AND METHOD OF PREPARING THEREOF
EP2573072A4 (en) INDENOCHINOLINE COMPOUND, METHOD OF MANUFACTURE AND APPLICATION THEREOF
EP2289967A4 (en) POLYHYDROXYALKANOATE COPOLYMER AND MANUFACTURING METHOD THEREFOR
EP2883914A4 (en) BIOLOGICAL ASPHALT, BIOLOGICAL ASPHALT COMPOUND AND METHOD OF MANUFACTURING THEREOF
BRPI1016182A2 (pt) método para o tratamento da leucemia mieloide aguda

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.